KUALA LUMPUR, Dec 21 -- ALR Technologies (ALRT or the Company), the diabetes management company, has released an open letter to shareholders from Chairman and Chief Executive Officer Sidney Chan.
“2021 has been a transformative year for ALRT within which we have accomplished many important milestones. Most notable is the formation of the animal health division.
“As discussed below, the successful launch of the GluCurve Pet CGM (Continuous Glucose Monitor) should lead to revenue, earnings, and positive cashflows in the second half of 2022.
“We have discussed partnership opportunities on the GluCurve Pet CGM with various interested pharmaceutical companies and have selected our top candidate and are targeting to finalise a definitive agreement by May 2022,” said Chan.
“Additionally, we have brought on key additions to the ALR Technologies corporate team, and we have laid the groundwork to revolutionise diabetes care in human health.
“I am grateful for the support of our current shareholders, and the interest we have received from potential institutional investors, investment funds, and retail investors alike.”
Chan continued in the letter: “Shareholders have asked how all the latest developments connect and fit into the company roadmap. So, I thought it prudent to discuss the following five topics to give a holistic overview of what we have accomplished, what we seek to accomplish in 2022, and why we have chosen this path to bring value to stakeholders.”
Based on a statement, the topics are Continuous Glucose Monitor, Human Health Initiative, Animal Health, Pharmaceutical Partnership, and Corporate Strategy.
The original letter can be found at https://alrt.com/investors/2021lettertoshareholders.
More details at https://sg.alrt.com.
-- BERNAMA
No comments:
Post a Comment